Download PDF
Pneumologie 2015; 69(05): 282-286
DOI: 10.1055/s-0034-1391920
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Kurze Übersicht über neue Medikamente zur Therapie der multiresistenten Tuberkulose[*]

New Drugs for the Treatment of Multidrug-resistant Tuberculosis (MDR-TB)
T. Schaberg
1   Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg
,
R. Otto-Knapp
2   Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK e.V.) und Klinik für Pneumologie der Lungenklinik Heckeshorn im Helios Klinikum Emil von Behring, Berlin
,
T. Bauer
2   Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK e.V.) und Klinik für Pneumologie der Lungenklinik Heckeshorn im Helios Klinikum Emil von Behring, Berlin
› Author Affiliations
Further Information

Publication History

eingereicht 15 February 2015

akzeptiert nach Revision 14 March 2015

Publication Date:
13 May 2015 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Dieser Artikel gibt einen kurzen Überblick über den Entwicklungsstand neuer Medikamente zur Therapie der multiresistenten Tuberkulose. Berichtet wird neben den zugelassenen Medikamenten Delamanid und Bedaquilin über Pretomanid, SQ109 und Sutezolid.

Abstract

This article summarizes the state of development of new drugs for the treatment of multidrug-resistant tuberculosis. We focused on delamanid, bedaquiline, pretomanid, SQ 109 and sutezolid.

* Dieser Artikel lehnt sich eng an eine Übersicht über Delamanid und Bedaquilin an, die im Jahre 2014 im 37. Informationsbericht des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose erschienen ist [1].


 

  • Literatur

  • 1 Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose e. V. 37. Informationsbericht. 2014: 108-125
    PubMedGoogle Scholar
  • 2 Diacon AH, Dawson R, du BoisJ et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 2012; 56: 3027-3031
    CrossrefPubMedGoogle Scholar
  • 3 Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993
    CrossrefPubMedGoogle Scholar
  • 4 Heinrich N, Dawson R, du Bois J et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 2015; DOI: 10.1093/jac/dku553.
    PubMedGoogle Scholar
  • 5 Wallis RS, Dawson R, Friedrich SO et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PloS one 2014; 9: e94462
    CrossrefPubMedGoogle Scholar
  • 6 Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-227
    CrossrefPubMedGoogle Scholar
  • 7 Huitric E, Verhasselt P, Andries K et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51: 4202-4204
    CrossrefPubMedGoogle Scholar
  • 8 Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-2835
    CrossrefPubMedGoogle Scholar
  • 9 Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405
    CrossrefPubMedGoogle Scholar
  • 10 Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276
    CrossrefPubMedGoogle Scholar
  • 11 Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732
    CrossrefPubMedGoogle Scholar
  • 12 Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control. 2013 62. 1-12
    PubMedGoogle Scholar
  • 13 Sasaki H, Haraguchi Y, Itotani M et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[1] [2]oxazoles. Journal of medicinal chemistry 2006; 49: 7854-7860
    CrossrefPubMedGoogle Scholar
  • 14 Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS medicine 2006; 3: e466
    CrossrefPubMedGoogle Scholar
  • 15 Mair SJ LK. A phase 1 trial to evaluate the safety, tolerability and pharmacokinetics of single and multiple oral doses of spray-dried OPC-67683 in healthy male and female subjects. Otsuka Study No. 242-05-101, Charles River Study No. 018044. Charles River Report No. 26515. 2006
    PubMedGoogle Scholar
  • 16 Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954
    CrossrefPubMedGoogle Scholar
  • 17 Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160
    CrossrefPubMedGoogle Scholar
  • 18 Skripconoka V, Danilovits M, Pehme L et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400
    CrossrefPubMedGoogle Scholar
  • 19 Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J et al. Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J 2015; 45: 1119-1131
    CrossrefPubMedGoogle Scholar